Functional Brain Imaging Laboratory
David Eidelberg, MD, Lab Head Head, Center for Neurosciences Investigator 350 Community Drive |
Academic Degrees:
B.A., 1977, Columbia University, New York, NY
M.D., 1981, Harvard Medical School, Boston, MA
Academic Appointments:
Susan and Leonard Feinstein Professor of Neurology and Neuroscience
- New York University School of Medicine
Research Overview:
Dr. Eidelberg directs a leading imaging research program in brain disease. His program is internationally recognized for developing novel imaging techniques to characterize and quantify neural circuits in neurodegenerative disorders and to study their modulation by treatment using functional imaging with PET and fMRI. Dr. Eidelberg and his colleagues have detected characteristic spatially distributed metabolic networks for Parkinson’s disease, Huntington’s disease, and other neurological conditions. The identification and quantification of these pathways is important for diagnosing disease and for assessing the extent of functional impairment with disease progression. This approach has also proved useful including neuroprotective agents designed to modify the course of disease.
Dr. Eidelberg has been the recipient of numerous grants and awards from the National Institutes of Health and other funding sources, including the Fred Springer Award of the American Parkinson’s Disease Association. He is the author of over 350 scientific publications and has served on the editorial boards of Neurology (1996-2001), Movement Disorders (1999-2003), Journal of Nuclear Medicine (1999-Present), Current Opinion in Neurology (2001-Present), Clinical Neuroscience Research (Associate Editor, 2003-2007), Annals of Neurology (2006-Present), and Molecular Imaging and Biology (Associate Editor, 2007-Present). He also serves on the scientific advisory board of The Michael J. Fox Foundation (2004-Present) and the Bachmann-Strauss Dystonia and Parkinson Foundation (2009-Present), and is Scientific Director of The Thomas Hartman Foundation for Parkinson’s Research (2007-Present).
Research Description:
Studies currently conducted at the Center for Neurosciences use functional brain imaging to map the abnormal neural circuitry underlying nervous system diseases such as Parkinson’s disease, Huntington’s disease, torsion dystonia, and the dementias. The quantification of these circuit abnormalities in living patients is critical diagnostically and for assessing the efficacy of new therapeutic interventions.
Dr. Eidelberg and his team of investigators use functional imaging to study neurological disease from a variety of computational and behavioral perspectives. In parallel with these efforts, researchers at The Feinstein’s radiochemistry facility have helped to develop new radiotracer techniques to quantify neurochemical deficits associated with neurodegenerative processes. This research is important for the development of new approaches to the treatment of these conditions. Likewise, investigators at the magnetic resonance center are developing new imaging applications to measure abnormal pathway connectivity in health and disease.
Current studies include:
Abnormal brain circuitry in normal aging and Parkinson’s disease
Investigators in the Functional Brain Imaging Laboratory are mapping the functional/anatomical circuitry underlying motor performance and learning in healthy aging and Parkinson’s disease.
Causes of cognitive dysfunction in Parkinson’s disease Investigators are elucidating the pathophysiology of certain types of cognitive dysfunction and mood disorder in Parkinson’s disease and related disorders.
Brain abnormalities pre-manifest carriers of genetic mutations for brain disease
Neuroscientists are using novel imaging methods to identify functional and anatomical abnormalities in the brains of individuals genetically at risk for brain diseases including Huntington’s disease, dystonia, and familial Parkinson’s disease.
Brain chemistry changes and treatment efficacy
Researchers are investigating the regulation of key neurotransmitters to understand how brain chemistry relates to network modulation and therapeutic outcome. Investigators are also using functional imaging techniques to quantify the central effects of levodopa as well as the time course of medication washout on brain function. Investigators are also utilizing network imaging techniques to shed light on mechanisms of treatment side effects (levodopa-induced dyskinesias) and novel therapies like gene therapy.
Natural history of neurological diseases
Researchers in the Center are involved in longitudinal studies of Parkinson's and Huntington’s disease to study the time course of network changes over time and the relationship of these changes to other disease biomarkers.
Abnormal protein aggregation in neurodegenerative disease
Investigators are studying the time course of abnormal protein aggregation in Parkinson’s disease and Alzheimer’s disease. They are also examining the relationship of these changes to metabolic network activity and cognitive functioning in these disorders.
Multi-modal imaging of brain function
Physicists and neuroscientists in the Center have developed a novel algorithm based on anatomical information from MRI to correct for the effect of brain atrophy, one of the major obstacles to accurate PET measurements in patients with neurodegenerative diseases. A team of investigators are studying the impact of these structural changes on abnormal brain network activity in pre-manifesting mutation carriers for Huntington’s disease.
Collaborations within the NS-LIJ Health System
Our Center maintains extensive collaborations with the Center for Genomics and Human Genetics, the Center for Alzheimer’s Disease and Memory Disorders, the Center for Translational Psychiatry, and the Center for Patient-Oriented Research at The Feinstein. Many investigators also are active as clinical specialists within the Health System, with close interactions with the Departments of Medicine and Neurology.
|
Name: Miklos Argyelan, MD Position: Research Scientist Research: Dr. Argyelan uses PET and fMRI to study Parkinson’s disease patients. His recent projects focus on learning and on the regulatory mechanism of dopamine. He hopes to shed light on the circumstances under which L-dopa facilitates or impairs learning. Email: margyela@nshs.edu |
|
Name: Matthew Bussa, MPH Position: Research Assistant Research: Matthew Bussa’s research interests are in studying metabolic brain networks in Parkinson’s disease and related movement disorders. Email: mbussa@nshs.edu |
|
Name: Maren Carbon-Carbon, PhD Position: Assistant Investigator Research: Dr. Carbon-Correll’s focuses on the use of functional brain imaging to study mechanisms of disease in hereditary dystonia. In addition, she studies the effects of deep brain stimulation on learning in dystonia and Parkinson’s disease. Email: mcarbon@nshs.edu |
|
Name: Vijay Dhawan, PhD Position: Associate Investigator Research: Dr. Dhawan’s research focuses on the use of novel radiotracers in functional brain imaging and studies the alterations in brain dopaminergic system that occurs in Parkinson's disease and other movement disorders. Email: vdhawan@nshs.edu |
|
Name: Yilong Ma, PhD Position: Associate Investigator Research: Dr. Ma works on the development and application of brain imaging methodology in the study of neurodegenerative and neuropsychiatric disorders. Email: yma@nshs.edu |
|
Name: Paul Mattis, PhD Position: Assistant Investigator Research: Dr. Mattis’ research focuses on the neuropsychology of movement disorders, including Parkinson’s disease and Huntington’s disease. He has a special interest in the relationship between cognitive functioning and metabolism brain networks. Email: pmattis@nshs.edu |
|
Name: Shichun Peng, PhD Position: Postdoctoral Research Fellow Research: Dr. Peng’s research interests are in medical image processing and analysis with a focus on pattern recognition and multi-modality correlation. Email: speng@nshs.edu |
|
Name: An Vo, PhD Position: Postdoctoral Research Fellow Research: Dr. Vo’s research interests are in fMRI processing and analysis. Email: apo@nshs.edu |
|
Name: Phoebe Spetsieris, PhD Position: Associate Investigator Research: Dr. Spetsieris uses an integrated methodologies approach to develop a versatile PC based package (SCANVP) that has been widely used in multi-modal functional image data visualization and analysis. Email: pspetsie@nshs.edu |
|
Name: Chengke Tang, MD Email: ctang@nshs.edu |
|
Name: Aziz Ulug, PhD Position: Associate Investigator Research: Dr. Ulug’s research focuses on neuroimaging applications of MR diffusion tensor imaging (DTI). He is also highly experienced in other functional applications of MRI such as fMRI and MRSI. Email: aulug@nshs.edu |
|
Name: Toni Flanagan, MS Position: Research Coordinator Research: Toni Flanagan is a research coordinator who manages research studies involving Dystonia and Parkinson’s disease. Email: tflanaga@nshs.edu |
|
Name: Loreta Quartarolo, BS Position: Research Coordinator Research: Loreta Quartarolo is a research coordinator who manages research studies involving Parkinson’s and Huntington’s disease. Email: lquartar@nshs.edu |
|
Name: Christine Edwards Position: Administrative Director Phone: (516) 562 1123 Email: cedwards@nshs.edu |
|
Name: Rosie Persaud Position: Administrative Assistant Phone: (516) 562 2498 Email: rpersaud@nshs.edu |
Publications (2007-Present)
Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, Ma Y, Bressman S, Eidelberg D. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology, 2009; in press
Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, Chaly T, Eidelberg D. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry 2009; Apr 15. [Epub ahead of print]
Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt M, Eidelberg D. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg, 2009; Mar 20 [Epub ahead of print]
Smith, G, Ma, Y, Dhawan, V, Chaly, T, Eidelberg, D. Selective Serotonin Reuptake Inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography (PET). Synapse, 2009; 63(1):1-6
Spetsieris P, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using functional PCA-based imaging features. NeuroImage, 2009; 45(4):1241-1252
Smith G, Kramer E, Ma Y, Hermann C, Dhawan V, Chaly T, Eidelberg D. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer’s disease. Brain, 2009; 132(2): 392-401
Carbon M, Ghilardi M-F, Argyelan M, Dhawan V, Bressman S, Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: An equiperformance study. Brain 2008; 131(1):146-154 [NIHMS: 57764]
Carbon M, Kingsley PB, Tang C, Bressman S, Eidelberg D. Microstructural white matter changes in primary torsion dystonia. Mov Disord 2008; 23(2):234-239 [NIHMS: 57765]
Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, Carbon M, Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci, 2008; 28(16):4201-4209 [PMCID: PMC2577921]
Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, Feigin A, Eidelberg D. Abnormal metabolic networks in atypical parkinsonism. Mov Disord, 2008; 23(5):727-733
Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson’s disease. Neurology, 2008; 70(16 Pt 2):1470-1477 [NIHMS: 57770]
Lin T, Carbon M, Tang C, Mogilner A, Sterio D, Beric A, Dhawan V, Eidelberg D. Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease. Brain, 2008; 131(Pt 5):1373-1380
Argyelan M, Carbon M, Ghilardi MF, Feigin A, Mattis P, Dhawan V, Eidelberg D. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci, 2008; 28(42):10687-10695 [NIHMS: 74170]
Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D. Subthalamic GAD gene therapy: Changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007; 27(3):501-509
Carbon M, Ghilardi MF, Dhawan V, Eidelberg D. Correlates of movement initiation and velocity in Parkinson’s disease: A longitudinal study. NeuroImage 2007; 34(1):361-370 [NIHMS: 57755]
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. NeuroImage 2007; 34(2):714-23. [NIHMS: 57756]
Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 2007; 22(2):167-173
Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: Test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27(3):597-605 [NIHMS: 57714]
Eckert T, Van Laere K, Lewis DE, Edwards C, Santens P, Eidelberg D. Quantification of PD-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007; 34(4):496-501
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson’s disease. Brain 2007; 130(Pt 7):1834-1846 [NIHMS: 57759]
Kaplitt M, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P, Bland R, Young D, Strybing K, Eidelberg D†, During M†. Safety and tolerability of AAV-GAD gene therapy for Parkinson’s disease: An open label, phase I trial. Lancet 2007; 369(9579):2097-2105 [† Shared senior authorship]
Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 2007; 130(Pt 11):2858-2867 [NIHMS: 57763]
Zgaljardic DJ, Borod JC, Foldi NS, Rocco M, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson’s disease. Cogn Behav Neurol 2007; 20:184-192 [NIHMS: 57761]
Feigin A, Kaplitt MG, Tang C, Lin T, Dhawan V, During MJ, Eidelberg D. Modulation of metabolic brain networks following subthalamic gene therapy for Parkinson’s disease. Proc Natl Acad Sci USA 2007; 104(49):19559-19564 [PMCID: PMC2148328]
Chapters, Reviews, and Editorials (Selected, 2007 – Present)
Carbon M, Eidelberg D. Abnormal structure/function relationships in hereditary dystonia. Neuroscience, 2009; Jan 1 [Epub ahead of print] [NIHMS: 85711] [Review]
Dhawan V, Eidelberg D. Mom and me: brain metabolism links Alzheimer’s disease to maternal genes. Neurology, 2009; 72(6):486-487 [Editorial]
Ma Y, Tang C, Moeller J, Eidelberg D. Abnormal regional brain function in Parkinson’s disease: Truth or fiction? NeuroImage, 2008; Oct 18 [Epub ahead of print] [PMID: 18992824]
Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiology of Disease, 2008; Nov 1 [Epub ahead of print] [PMID: 19013242]
Bateman RJ, Eidelberg D. Testing a test for Alzheimer’s disease. Neurology 2007; 68(7):482-483 [Editorial]
Eckert T, Zgaljardic D, Eidelberg D. Functional imaging and therapeutics in Parkinson’s disease. In: Clinical applications of functional brain MRI. S. Rombouts, P. Scheltens, F. Barkhof, editors. Oxford: Oxford University Press; 2007:285-310
Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson’s disease and Huntington’s disease. Mol Imag Biol 2007; 9(4):223-233 [Review] [NIHMS: 57781]
Feigin A, Eidelberg D. Gene transfer therapy for neurodegenerative disorders. Mov Disorders 2007; 22(9):1223-1228 [Review]
Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol 2007;6:926-932 [Review] [NIHMS: 57783]
Ma Y, Eidelberg D. Multivariate brain mapping in clinical neuroscience research. Clin Neurosci Res 2007; 6(6):357-358 [Editorial]